Impact of minimal invasive extracorporeal circulation on systemic inflammatory response - a randomized trial.


Journal

Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 21 03 2024
accepted: 15 06 2024
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 3 7 2024
Statut: epublish

Résumé

Extracorporeal circulation causes a systemic inflammatory response, that may cause postoperative haemodynamic instability and end-organ dysfunction. This study aimed to investigate the impact of minimal invasive extracorporeal circulation (MiECC) on the systemic inflammatory response compared with conventional extracorporeal circulation (CECC). Patients undergoing coronary artery bypass grafting were randomized to MiECC (n = 30) and CECC (n = 30). Primary endpoint was tumor necrosis factor-α. Secondary endpoints were other biochemical markers of inflammation (IL1β, IL6 and IL8, C-reactive protein, leukocytes), and markers of inadequate tissue perfusion and tissue damage (lactate dehydrogenase, lactate and creatine kinase-MB). In addition, we registered signs of systemic inflammatory response syndrome, haemodynamic instability, atrial fibrillation, respiratory dysfunction, and infection. Patients treated with MiECC showed significantly lower levels of tumor necrosis factor-α than CECC during and early after extracorporeal circulation (median: MiECC 3.4 pg/mL; CI 2.2-4.5 vs. CECC 4.6 pg/mL; CI 3.4-5.6; p = 0.01). Lower levels of creatine kinase-MB and lactate dehydrogenase suggested less tissue damage. However, we detected no other significant differences in any other markers of inflammation, tissue damage or in any of the clinical outcomes. Lower levels of TNF-α after MiECC compared with CECC may reflect reduced inflammatory response, although other biochemical markers of inflammation were comparable. Our results suggest better end-organ protection with MiECC compared with CECC. Clinical parameters related to systemic inflammatory response were comparable in this study. NCT03216720.

Sections du résumé

BACKGROUND BACKGROUND
Extracorporeal circulation causes a systemic inflammatory response, that may cause postoperative haemodynamic instability and end-organ dysfunction. This study aimed to investigate the impact of minimal invasive extracorporeal circulation (MiECC) on the systemic inflammatory response compared with conventional extracorporeal circulation (CECC).
METHODS METHODS
Patients undergoing coronary artery bypass grafting were randomized to MiECC (n = 30) and CECC (n = 30). Primary endpoint was tumor necrosis factor-α. Secondary endpoints were other biochemical markers of inflammation (IL1β, IL6 and IL8, C-reactive protein, leukocytes), and markers of inadequate tissue perfusion and tissue damage (lactate dehydrogenase, lactate and creatine kinase-MB). In addition, we registered signs of systemic inflammatory response syndrome, haemodynamic instability, atrial fibrillation, respiratory dysfunction, and infection.
RESULTS RESULTS
Patients treated with MiECC showed significantly lower levels of tumor necrosis factor-α than CECC during and early after extracorporeal circulation (median: MiECC 3.4 pg/mL; CI 2.2-4.5 vs. CECC 4.6 pg/mL; CI 3.4-5.6; p = 0.01). Lower levels of creatine kinase-MB and lactate dehydrogenase suggested less tissue damage. However, we detected no other significant differences in any other markers of inflammation, tissue damage or in any of the clinical outcomes.
CONCLUSIONS CONCLUSIONS
Lower levels of TNF-α after MiECC compared with CECC may reflect reduced inflammatory response, although other biochemical markers of inflammation were comparable. Our results suggest better end-organ protection with MiECC compared with CECC. Clinical parameters related to systemic inflammatory response were comparable in this study.
CLINICAL REGISTRATION NUMBER BACKGROUND
NCT03216720.

Identifiants

pubmed: 38961388
doi: 10.1186/s13019-024-02903-8
pii: 10.1186/s13019-024-02903-8
doi:

Substances chimiques

Biomarkers 0
Tumor Necrosis Factor-alpha 0

Banques de données

ClinicalTrials.gov
['NCT03216720']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

418

Subventions

Organisme : Medtronic External Research Program
ID : ERP-2018-11272
Organisme : NIH/NCRR Colorado CTSI
ID : UL1 RR025780 (REDCap)
Organisme : Health Research Foundation of Central Denmark Region
ID : A 3057

Informations de copyright

© 2024. The Author(s).

Références

Fromes Y, Gaillard D, Ponzio O, Chauffert M, Gerhardt M-F, Deleuze P, et al. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg. 2002;22(4):527–33.
doi: 10.1016/S1010-7940(02)00372-X pubmed: 12297167
Kraft F, Schmidt C, van Aken H, Zarbock A. Inflammatory response and extracorporeal circulation. Best Pract Res Clin Anaesthiol. 2015;29(2):113–23.
doi: 10.1016/j.bpa.2015.03.001
Huybregts RAJM, Morariu AM, Rakhorst G, Spiegelenberg SR, Romijn HWA, de Vroege R, et al. Attenuated renal and intestinal Injury after Use of a Mini-cardiopulmonary Bypass System. Ann Thorac Surg. 2007;83(5):1760–6.
doi: 10.1016/j.athoracsur.2007.02.016 pubmed: 17462395
Bical OM, Fromes Y, Gaillard D, Fischer M, Ponzio O, Deleuze P, et al. Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery. Eur J Cardiothorac Surg. 2006;29(5):699–702.
doi: 10.1016/j.ejcts.2006.01.053 pubmed: 16520053
Meldrum DR. Tumor necrosis factor in the heart. 1998. Am J Physiol. 1998;274(3):577–95.
McGuinness J, Bouchier-Hayes D, Redmond JM. Understanding the inflammatory response to cardiac surgery. Surgeon. 2008;6(3):162–71.
doi: 10.1016/S1479-666X(08)80113-8 pubmed: 18581753
Remadi J, Rakatoarivelo Z, Marticho P, Benamar A. Prospective randomized study comparing coronary artery bypass grafting with the new mini-extracorporeal circulation Jostra system or with a standard cardiopulmonary bypass. Am Heart J. 2006;151:e1981–7.
doi: 10.1016/j.ahj.2005.03.067
Svitek V, Lonsky V, Mandak J, Krejsek J, Kolackova M, Brzek V, et al. No clear clinical benefit of using mini-invasive extracorporeal circulation in coronary artery bypass grafting in low-risk patients. Perfusion. 2009;24(6):389–95.
doi: 10.1177/0267659109359437 pubmed: 20093333
Beghi C, Nicolini F, Agostinelli A, Borrello B, Budillon AM, Bacciottini F, et al. Mini-cardiopulmonary Bypass System: results of a prospective Randomized Study. Ann Thorac Surg. 2006;81:1396–400.
doi: 10.1016/j.athoracsur.2005.10.015 pubmed: 16564279
Farneti PA, Sbrana S, Spiller D, Cerillo AG, Santarelli F, Dario DD, et al. Reduction of blood coagulation and monocyte-platelet interaction following the use of a minimal extracorporeal circulation system (Synergy
doi: 10.1177/0267659108091336 pubmed: 18788218
Vohra HA, Whistance R, Modi A, Ohri SK. The inflammatory response to miniatuarised extracorporeal circulation: a review of the literature. Mediators Inflamm. 2009;2009:707042. https://doi.org/10.1155/2009/707042 .
doi: 10.1155/2009/707042 pubmed: 20101278
Wiesenack C, Liebold A, Philipp A, Ritzka M, Koppenberg J, Birnbaum DE, et al. Four years’ experience with a miniaturized extracorporeal circulation system and its influence on clinical outcome. Artif Organs. 2004;28(12):1082–8.
doi: 10.1111/j.1525-1594.2004.00030.x pubmed: 15554936
Harris PA, Taylor R, Minor BL, Elliot V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208. https://doi.org/10.1016/j.jbi.2019.103208 .
doi: 10.1016/j.jbi.2019.103208
Modrau IS, Halle DR, Nielsen PH, Kimose HH, Greisen JR, Kremke M, et al. Impact of minimally invasive extracorporeal circulation on coagulation—a randomized trial. Eur J Cardiothorac Surg. 2020;57(6):1145–53.
doi: 10.1093/ejcts/ezaa010 pubmed: 32011717 pmcid: 7239600
Media AS, Juhl-Olsen P, Magnusson NE, Modrau IS. The impact of minimal invasive extracorporeal circulation on postoperative kidney function. Perfusion. 2021;36(7):745–50.
doi: 10.1177/0267659120954601 pubmed: 32921252
Anastasiadis K, Murkin J, Antonitsis P, Bauer A, Ranucci M, Gygax E, et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the minimal invasive Extra-corporeal technologies international society (MiECTiS). Interact Cardiovasc Thorac Surg. 2016;22(5):647–62.
doi: 10.1093/icvts/ivv380 pubmed: 26819269 pmcid: 4892134
Olsen MA, Sundt TM, Lawton JS, Damiano RJ Jr, Hopkins-Broyles D, Lock-Buckley P, et al. Risk factors for leg harvest surgical site infections after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2003;126(4):992–9.
doi: 10.1016/S0022-5223(03)00200-9 pubmed: 14566237
Lazar HL, Salm TV, Engelman R, Orgill D, Gordon S. Prevention and management of sternal wound infections. J Thorac Cardiovasc Surg. 2016;152(4):962–72.
doi: 10.1016/j.jtcvs.2016.01.060 pubmed: 27555340
Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence. 2014;5(1):20–6.
doi: 10.4161/viru.27135 pubmed: 24280933
Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II Eur J Surg. 2012;41:734–44. discussion 744–5.
Bauer A, Hausmann H, Schaarschmidt J, Scharpenberg M, Troitzsch D, Johansen P, et al. Shed-blood-separation and cell-saver: an integral part of MiECC? Shed-blood-separation and its influence on the perioperative inflammatory response during coronary revascularization with minimal invasive extracorporeal circulation systems – a randomized controlled trial. Perfusion. 2018;33(2):136–47.
doi: 10.1177/0267659117728195 pubmed: 28937313
Westerberg M, Gäbel J, Bengtsson A, Sellgren J, Eidem O, Jeppsson A. Hemodynamic effects of cardiotomy suction blood. J Thorac Cardiovasc Surg. 2006;131(6):1352–7.
doi: 10.1016/j.jtcvs.2005.12.067 pubmed: 16733169
Formica F, Mariani S, Broccolo F, Caruso R, Corti F, D’Alessandro S, et al. Systemic and myocardial inflammatory response in coronary artery bypass graft surgery with miniaturized extracorporeal circulation. ASAIO J. 2013;59(6):600–6.
doi: 10.1097/MAT.0b013e3182a817aa pubmed: 24172265
Jaffer U, Wade RG, Gourlay T. Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth. 2010;2(3):161–75.
pubmed: 23441054 pmcid: 3484588
Baumbach H, Rustenbach CJ, Ahad S, Nagib R, Albert M, Ratge D, et al. Minimally invasive extracorporeal bypass in minimally invasive heart valve operations: a prospective randomized trial. Ann Thorac Surg. 2016;102:93–101.
doi: 10.1016/j.athoracsur.2016.01.043 pubmed: 27101726
Yuan SM, Lin HZ. Interleukin-6 in cardiac surgery. Periodicum Biologorum. 2017;119(2):93–9.
doi: 10.18054/pb.v119i2.4928
Yu QB, Li HM, Li LL, Wang SY, Wu YB. Sevoflurane downregulates interleukin-6 and interleukin-8 levels in patients after cardiopulmonary bypass surgery: a meta-analysis. Genet Mol Res. 2015;14(4):19016–27.
doi: 10.4238/2015.December.29.9 pubmed: 26782552
Skrabal CA, Steinhoff G, Liebold A. Minimizing cardiopulmonary bypass attenuates myocardial damage after cardiac surgery. ASAIO J. 2007;53:32–5.
doi: 10.1097/01.mat.0000249868.96923.1e pubmed: 17237646
Peivandi AA, Dahm M, Vulcu S, Peetz D, Hafner G, Oelert H. Troponin I concentrations of shed blood might influence monitoring of myocardial injury after coronary operations. Transfus Apher Sci. 2001;25(3):157–62.
doi: 10.1016/S1473-0502(01)00111-2 pubmed: 11846129
Wahba A, Milojevic M, Boer C, de Somer FMJJ, Gudbjartsson T, van den Goor J, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg. 2020;57(2):210–51.
pubmed: 31576396
Laffey JG, Boylan JF, Cheng DCH. The systemic inflammatory response to cardiac surgery. Anesthesiology. 2002;97(1):215–52.
doi: 10.1097/00000542-200207000-00030 pubmed: 12131125
Squiccimarro E, Labriola C, Malvindi PG, Margari V, Guida P, Visicchio G, et al. Prevalence and clinical impact of systemic inflammatory reaction after cardiac surgery. J Cardiothorac Vasc Anesth. 2019;33(6):1682–90.
doi: 10.1053/j.jvca.2019.01.043 pubmed: 30772177

Auteurs

Deborah Richards Halle (DR)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.

Leila Louise Benhassen (LL)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark. benhassen@clin.au.dk.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. benhassen@clin.au.dk.

Karsten Lund Søberg (KL)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.

Peter Fast Nielsen (PF)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.

Hans-Henrik Kimose (HH)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Adrian Bauer (A)

Dept. of Cardiovascular Perfusion, MediClin Heart Centre Coswig, Coswig, Germany.

John Michael Hasenkam (JM)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Ivy Susanne Modrau (IS)

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH